Full-Time
Contract Analyst
Icon
10,001+ employees
Global drug and device development services
No salary listed
Reading, UK
Hybrid
Must be within commuting distance of London; one office day per week is required.
Bachelor's
 Accounting (1) |
|---|
Get referred to Icon
See people who can refer or advise you
- A bachelor's degree in Finance, Accounting, Business Administration, or a related field is required.
- Experience with site-level contracts and the Interactive Costing Tool is required.
- Prior experience in a contract-related role within a contract research organization, pharmaceutical, or academic environment is required.
- Strong analytical skills to interpret complex data are required.
- Excellent communication and interpersonal skills are required.
- The ability to manage multiple tasks and meet deadlines is required.
- Willingness to travel approximately 5% is required.
- Legal authorization to work in the United Kingdom is required.
- Prepare, verify, and execute invoicing through electronic processing and reporting for an assigned portfolio of accounts.
- Balance and maintain client relationships.
- Reconcile accounts and investigate discrepancies.
- Keep abreast of contract progression concerning invoicing units.
- Interact closely with the Revenue team to ensure timely billing and investigate discrepancies for assigned clients.
Provides consulting, development, and commercialization services for drugs and medical devices through a global network to help clients accelerate development and bring products to market. A global team of experts in 53 countries offers end-to-end support across strategy, development, regulatory, manufacturing, and market access to reduce time to market, lower costs, and improve quality. The company differentiates itself with its large global presence, clear focus on speed and cost, and extensive experience across therapeutic areas. Its goal is to help clients accelerate the development of life-saving drugs and devices by delivering high-quality information, solutions, and performance.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Get referred to Icon
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 1.2% year over year to $2.06 billion.
- Gross bookings climbed 24.1% year over year, signaling stronger biotech demand.
- Closing Symphony Health on May 8, 2026 sharpened focus on core clinical research.
What critics are saying
- Audit Committee restatements cut 2024 revenue $92.7 million and exposed material weaknesses.
- 2026 revenue guidance of $7.85 billion to $8.15 billion trails 2025's $8.25 billion.
- Debt refinancing through April 2027 bridge financing leaves maturity pressure unresolved.
What makes Icon unique
- ICON’s 23.4 billion backlog and 1.51x Q2 2026 book-to-bill beat peers.
- Anthropic and Microsoft partnerships embed Orbis AI across trial planning and execution.
- Global scale still matters: 40,200 employees across 99 locations in 55 countries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 29%1 year growth
↑ 31%2 year growth
↑ 31%Insider selling: Icon (NASDAQ:ICLR) CEO sells $62,674.74 in stock. August 11, 2026 Key points. * Icon CEO Barry Edward Balfe sold 382 shares for approximately $62,675, reducing his direct holdings by 7.37%. The sale was made to cover tax withholding obligations tied to vested equity awards. * Icon reported quarterly EPS of $2.56, narrowly exceeding estimates, while revenue reached $2.06 billion and increased 2.3% year over year. * Analyst sentiment is mixed, with a consensus rating of "Hold" and an average price target of $170.40; institutional investors own 95.61% of the company. * MarketBeat previews the top five stocks to own by September 1st. Icon Plc (NASDAQ:ICLR - Get Free Report) CEO Barry Edward Balfe sold 382 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $164.07, for a total value of $62,674.74. Following the sale, the chief executive officer directly owned 4,804 shares in the company, valued at approximately $788,192.28. The trade was a 7.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Icon price performance. Icon stock traded down $0.47 during midday trading on Tuesday, reaching $165.58. 656,816 shares of the company were exchanged, compared to its average volume of 1,388,886. The firm's 50-day simple moving average is $160.91 and its 200-day simple moving average is $134.45. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The company has a market capitalization of $12.68 billion, a price-to-earnings ratio of 38.87, a P/E/G ratio of 6.82 and a beta of 1.21. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. Icon (NASDAQ:ICLR - Get Free Report) last released its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $3.26 EPS. On average, analysts anticipate that Icon Plc will post 9.57 EPS for the current year. Analyst ratings changes. ICLR has been the subject of several recent analyst reports. Leerink Partners set a $145.00 target price on shares of Icon in a research note on Thursday, May 28th. Truist Financial reissued a "buy" rating and set a $209.00 price target (up from $207.00) on shares of Icon in a research note on Friday, July 31st. UBS Group set a $160.00 price objective on Icon in a report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price objective on Icon from $130.00 to $155.00 and gave the company a "neutral" rating in a research report on Thursday, June 25th. Finally, William Blair upgraded Icon to a "strong-buy" rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $170.40. Discover more Market cap calculator AI infrastructure stocks Mathematics Institutional investors weigh in on Icon. A number of institutional investors have recently bought and sold shares of ICLR. WINTON GROUP Ltd purchased a new position in Icon during the second quarter worth approximately $254,000. Daiwa Securities Group Inc. grew its stake in shares of Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company's stock valued at $4,094,000 after buying an additional 4,546 shares during the period. Frontier Capital Management Co. LLC grew its stake in shares of Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company's stock valued at $10,379,000 after buying an additional 35,253 shares during the period. Peapack Gladstone Financial Corp acquired a new stake in shares of Icon during the 2nd quarter worth $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Icon by 58.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company's stock worth $113,000 after buying an additional 289 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors. About Icon. Icon plc NASDAQ: ICLR is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas. Icon's service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Icon, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Icon wasn't on the list. While Icon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
ICON plc has priced $2.15 billion in senior unsecured notes through its subsidiary, ICON Investments Six Designated Activity Company. The offering comprises three tranches: $500 million of 5.064% notes due 2029, $1.0 billion of 5.421% notes due 2031, and $650 million of 5.995% notes due 2036. The notes will be guaranteed by ICON on a senior unsecured basis. The offering is expected to close on 13 August 2026, subject to customary closing conditions. ICON intends to use proceeds to repay all outstanding borrowings under its bridge facility credit agreement, repay all outstanding senior secured term loans, and redeem its 5.809% Senior Secured Notes due 2027. Upon repayment, collateral securing ICON's revolving credit facility will be automatically released.
ICON Public Limited Company shares rose 33.2% over three months amid strengthening recovery signs in clinical research demand. Request-for-proposal flow increased 22% sequentially in Q2 2026, with Phase III programmes representing about 50% of opportunity volume. Gross bookings reached $3.68 billion, up 24.1% year-over-year, whilst net business wins totalled $3.12 billion. The book-to-bill ratio stood at 1.51X. Backlog grew 3% sequentially to $23.4 billion, improving revenue visibility. However, second-quarter adjusted EBITDA declined 21.7% year-over-year to $327.2 million, whilst adjusted earnings fell to $2.56 per share from $3.52. Higher pass-through revenues supported sales but pressured margins. Analysts expect 2026 revenues to decline 1% and earnings to fall 15.3% year-over-year.
ICON plc, a clinical research organisation, announced that shareholders approved all resolutions at its Annual General Meeting held on 31 July 2026. The resolutions, which were sent to shareholders on 26 June 2026, included the re-election of several board members and the election of new directors. The approved resolutions covered various corporate governance matters, including authorising the company to allot shares, disapply statutory pre-emption rights, and make overseas market purchases of shares. Shareholders also authorised the price range for reissuing treasury shares. Headquartered in Dublin, ICON employed approximately 40,200 people across 99 locations in 55 countries as of 30 June 2026. The company provides clinical development and commercialisation solutions to pharmaceutical, biotechnology, medical device, and public health organisations worldwide.
ICON plc has announced a multi-year collaboration with Anthropic to integrate Claude's AI capabilities throughout the clinical trial lifecycle. The partnership will advance ICON's Orbis platform, developing four production capabilities: site intelligence and study planning, predictive intelligence for enrolment risks, protocol optimisation, and ecosystem integration. ICON will deploy Claude across its organisation through role-based implementations, including Claude Code for developers and Claude Science for scientific teams. The collaboration will strengthen Orbis's intelligence layer, connecting ICON's expertise and data across trials. Chief Executive Officer Barry Balfe stated the partnership aims to accelerate clinical trials by combining ICON's clinical development expertise with Anthropic's frontier AI capabilities, helping sponsors make better decisions and execute studies with greater precision.